<VariationArchive RecordType="classified" VariationID="694389" VariationName="NM_000551.4(VHL):c.530_536del (p.Arg177fs)" VariationType="Deletion" Accession="VCV000694389" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2019-11-16" MostRecentSubmission="2019-11-16">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="682317" VariationID="694389">
      <GeneList>
        <Gene Symbol="LOC107303340" FullName="3p25 von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase Alu-mediated recombination region" GeneID="107303340" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10142339" stop="10160352" display_start="10142339" display_stop="10160352" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="VHL" FullName="von Hippel-Lindau tumor suppressor" GeneID="7428" HGNC_ID="HGNC:12687" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>3p25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10141778" stop="10153667" display_start="10141778" display_stop="10153667" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10183318" stop="10195353" display_start="10183318" display_stop="10195353" Strand="+" />
          </Location>
          <OMIM>608537</OMIM>
          <Haploinsufficiency last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2022-05-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=VHL">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000551.4(VHL):c.530_536del (p.Arg177fs)</Name>
      <CanonicalSPDI>NC_000003.12:10149849:GGAGACTGGA:GGA</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>3p25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="3" Accession="NC_000003.12" start="10149850" stop="10149856" display_start="10149850" display_stop="10149856" variantLength="7" positionVCF="10149849" referenceAlleleVCF="AGGAGACT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="3" Accession="NC_000003.11" start="10191534" stop="10191540" display_start="10191534" display_stop="10191540" variantLength="7" positionVCF="10191533" referenceAlleleVCF="AGGAGACT" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>R136fs</ProteinChange>
      <ProteinChange>R177fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_322" sequenceAccession="LRG_322">
            <Expression>LRG_322:g.13219_13225del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.11" sequenceAccession="NC_000003" sequenceVersion="11" change="g.10191537_10191543del" Assembly="GRCh37">
            <Expression>NC_000003.11:g.10191537_10191543del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000003.12" sequenceAccession="NC_000003" sequenceVersion="12" change="g.10149853_10149859del" Assembly="GRCh38">
            <Expression>NC_000003.12:g.10149853_10149859del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008212.3" sequenceAccession="NG_008212" sequenceVersion="3" change="g.13219_13225del">
            <Expression>NG_008212.3:g.13219_13225del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046756.1" sequenceAccession="NG_046756" sequenceVersion="1" change="g.7615_7621del">
            <Expression>NG_046756.1:g.7615_7621del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000551.4" sequenceAccession="NM_000551" sequenceVersion="4" change="c.530_536del" MANESelect="true">
            <Expression>NM_000551.4:c.530_536del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000542.1" sequenceAccession="NP_000542" sequenceVersion="1" change="p.Arg177fs">
            <Expression>NP_000542.1:p.Arg177fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001354723.2" sequenceAccession="NM_001354723" sequenceVersion="2" change="c.*84_*90del">
            <Expression>NM_001354723.2:c.*84_*90del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001624" Type="3 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_198156.3" sequenceAccession="NM_198156" sequenceVersion="3" change="c.407_413del">
            <Expression>NM_198156.3:c.407_413del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_937799.1" sequenceAccession="NP_937799" sequenceVersion="1" change="p.Arg136fs">
            <Expression>NP_937799.1:p.Arg136fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000551.3" sequenceAccession="NM_000551" sequenceVersion="3" change="c.530_536delGACTGGA">
            <Expression>NM_000551.3:c.530_536delGACTGGA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1575932266" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000551.4(VHL):c.530_536del (p.Arg177fs) AND multiple conditions" Accession="RCV000855722" Version="1">
        <ClassifiedConditionList TraitSetID="51290">
          <ClassifiedCondition DB="MedGen" ID="C1332900">Cerebellar hemangioblastoma</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1336839">Papillary renal cell carcinoma type 1</ClassifiedCondition>
          <ClassifiedCondition>Skin adenoma</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0019562">Von Hippel-Lindau syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2017-08-16" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2017-08-16" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-11-16" MostRecentSubmission="2019-11-16">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">31823746</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="51290" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6116" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Von Hippel-Lindau syndrome</ElementValue>
                <XRef ID="Von+Hippel-Lindau+syndrome/7416" DB="Genetic Alliance" />
                <XRef ID="46659004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">VHL syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Von Hippel-Lindau</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">VHLS</ElementValue>
                <XRef Type="MIM" ID="193300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Von Hippel-Lindau (VHL) syndrome is characterized by hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts, and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL syndrome and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.</Attribute>
                <XRef ID="NBK1463" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7855" />
                <XRef ID="7855" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000314230" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528276" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562500" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552165" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000553528" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569658" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301636</ID>
                <ID Source="BookShelf">NBK1463</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Renal cell carcinoma genetics">
                <ID Source="PubMed">26389510</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Von Hippel-Lindau">
                <URL>https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/vhl-syndrome</URL>
                <CitationText>PDQÂ® Cancer Genetics Editorial Board. PDQ Von Hippel-Lindau Disease. Bethesda, MD: National Cancer Institute. Updated &lt;03/08/2021&gt;. Accessed &lt;05/05/2021&gt;.</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="892" DB="Orphanet" />
              <XRef ID="C0019562" DB="MedGen" />
              <XRef ID="MONDO:0008667" DB="MONDO" />
              <XRef Type="MIM" ID="193300" DB="OMIM" />
            </Trait>
            <Trait ID="15845" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Renal adenocarcinoma</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Renal cell carcinoma 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Renal cell carcinoma, somatic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">RENAL CELL CARCINOMA, PAPILLARY, 1, SOMATIC</ElementValue>
                <XRef Type="Allelic variant" ID="164860.0006" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Papillary renal cell carcinoma type 1</ElementValue>
                <XRef ID="HP:0011797" DB="Human Phenotype Ontology" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">RCCP1</ElementValue>
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="605074" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="13215" />
                <XRef ID="13215" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <XRef ID="47044" DB="Orphanet" />
              <XRef ID="C1336839" DB="MedGen" />
              <XRef Type="MIM" ID="605074" DB="OMIM" />
              <XRef Type="primary" ID="HP:0011797" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="43063" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Skin adenoma</ElementValue>
              </Name>
            </Trait>
            <Trait ID="9770" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Cerebellar hemangioblastoma</ElementValue>
                <XRef ID="HP:0006880" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0003901" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemangioblastoma, sporadic cerebellar</ElementValue>
                <XRef ID="HP:0006880" DB="Human Phenotype Ontology" />
              </Name>
              <XRef ID="C1332900" DB="MedGen" />
              <XRef ID="MONDO:0003901" DB="MONDO" />
              <XRef Type="primary" ID="HP:0006880" DB="Human Phenotype Ontology" />
              <XRef Type="secondary" ID="HP:0006761" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1960906" SubmissionDate="2019-11-14" DateLastUpdated="2019-11-16" DateCreated="2019-11-16">
        <ClinVarSubmissionID localKey="SUB6166727" submittedAssembly="not applicable" title="SUB6166727" />
        <ClinVarAccession Accession="SCV000963100" DateUpdated="2019-11-16" DateCreated="2019-11-16" Type="SCV" Version="1" SubmitterName="Cancer medicine, Gaomi People's Hospital" OrgID="507133" OrganizationCategory="clinic" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-08-16">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variation (c.530_536delGACTGGA in VHL) is pathogenic, leading to hemangioblastoma in cerebellar tumors, metastasis of renal carcinoma and bilateral multiple nephridial cysts. This mutation may result in the alterations of the amino acid at position 177 (arginine) and the subsequent amino acids to form an abnormal VHL protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>inherited</Origin>
              <Ethnicity>Asian</Ethnicity>
              <GeographicOrigin>China</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <Age Type="minimum" age_unit="years">31</Age>
              <Age Type="maximum" age_unit="years">54</Age>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>mixed</Gender>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <TypePlatform>Sanger sequencing</TypePlatform>
              <MethodType>clinical testing</MethodType>
              <MethodAttribute>
                <Attribute Type="TestName">Applied Biosystems 3500 Dx Series Genetic Analyzer</Attribute>
              </MethodAttribute>
              <ObsMethodAttribute>
                <Attribute Type="TestingLaboratory" dateValue="2017-08-16">Beijing Shengguzhi Medical Laboratory</Attribute>
                <Comment>Pathogenic</Comment>
              </ObsMethodAttribute>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000551.3:c.530_536delGACTGGA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="193300" />
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Renal cell carcinoma</ElementValue>
            </Name>
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Cerebellar hemangioblastoma</ElementValue>
            </Name>
          </Trait>
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Skin adenoma</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6166727</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1960906" TraitType="Disease" MappingType="Name" MappingValue="Skin adenoma" MappingRef="Preferred">
        <MedGen CUI="None" Name="Skin adenoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1960906" TraitType="Disease" MappingType="XRef" MappingValue="193300" MappingRef="OMIM">
        <MedGen CUI="C0019562" Name="Von Hippel-Lindau syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1960906" TraitType="Disease" MappingType="Name" MappingValue="Renal cell carcinoma" MappingRef="Preferred">
        <MedGen CUI="C0007134" Name="Renal cell carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1960906" TraitType="Disease" MappingType="Name" MappingValue="Cerebellar hemangioblastoma" MappingRef="Preferred">
        <MedGen CUI="C1332900" Name="Cerebellar hemangioblastoma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

